US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US5747469A
(en)
*
|
1991-03-06 |
1998-05-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising DNA damaging agents and p53
|
CA2108144A1
(fr)
|
1991-03-06 |
1992-09-07 |
Jack A. Roth |
Methodes et compositions pour l'inhibition selective de l'expression genique
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
US6261834B1
(en)
*
|
1991-11-08 |
2001-07-17 |
Research Corporation Technologies, Inc. |
Vector for gene therapy
|
US5587308A
(en)
*
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
US6268213B1
(en)
|
1992-06-03 |
2001-07-31 |
Richard Jude Samulski |
Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
|
US6348352B1
(en)
|
1992-09-18 |
2002-02-19 |
Canji, Inc. |
Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
|
US5830461A
(en)
*
|
1992-11-25 |
1998-11-03 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Methods for promoting wound healing and treating transplant-associated vasculopathy
|
US5658565A
(en)
*
|
1994-06-24 |
1997-08-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Inducible nitric oxide synthase gene for treatment of disease
|
US6340674B1
(en)
|
1993-03-26 |
2002-01-22 |
Thomas Jefferson University |
Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
|
DE69435118D1
(de)
*
|
1993-04-30 |
2008-08-28 |
Wellstat Biologics Corp |
Gereinigte Zusammensetzungen von Newcastle-Krankheitvirus
|
US6686200B1
(en)
*
|
1993-08-31 |
2004-02-03 |
Uab Research Foundation |
Methods and compositions for the large scale production of recombinant adeno-associated virus
|
WO1997003703A1
(fr)
*
|
1995-07-21 |
1997-02-06 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Liposomes viraux adeno-associes et leur utilisation pour la transfection de cellules dendritiques pour stimuler l'immunite specifique
|
US6652850B1
(en)
|
1993-09-13 |
2003-11-25 |
Aventis Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
US5834441A
(en)
*
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
US5693531A
(en)
*
|
1993-11-24 |
1997-12-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vector systems for the generation of adeno-associated virus particles
|
FR2716893B1
(fr)
*
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
IL113052A0
(en)
|
1994-03-23 |
1995-06-29 |
Rhone Poulenc Rorer Sa |
Recombinant viruses, their preparation and their use in gene therapy
|
DE4411402A1
(de)
*
|
1994-03-31 |
1995-10-05 |
Juergen Schrader |
DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
|
AU2283895A
(en)
*
|
1994-04-11 |
1995-10-30 |
Sloan-Kettering Institute For Cancer Research |
Defective herpes and defective adeno-associated virus vectors with p53 for the treatment of cancer
|
ATE386131T1
(de)
|
1994-04-13 |
2008-03-15 |
Univ Rockefeller |
Aav-vermittelte überbringung von dna in zellen des nervensystems
|
WO1995032225A1
(fr)
*
|
1994-05-23 |
1995-11-30 |
The Salk Institute For Biological Studies |
Procede d'integration en des sites specifiques d'acides nucleiques, et produits associes
|
US6814962B1
(en)
*
|
1994-06-02 |
2004-11-09 |
Aventis Pharma S.A. |
Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US5658785A
(en)
*
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US6204059B1
(en)
*
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
EP0699754B2
(fr)
|
1994-08-12 |
2009-08-12 |
The University of Utah Research Foundation |
Méthode de diagnose pour la prédisposition au cancer du sein et des ovaires
|
CN1172502A
(zh)
|
1994-08-12 |
1998-02-04 |
亿万遗传股份有限公司 |
17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性
|
US5871986A
(en)
|
1994-09-23 |
1999-02-16 |
The General Hospital Corporation |
Use of a baculovirus to express and exogenous gene in a mammalian cell
|
US5652225A
(en)
*
|
1994-10-04 |
1997-07-29 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Methods and products for nucleic acid delivery
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
DE69534166T2
(de)
*
|
1994-10-28 |
2006-03-09 |
Trustees Of The University Of Pennsylvania |
Rekombinanter adenovirus und methoden zu dessen verwendung
|
US5872005A
(en)
*
|
1994-11-03 |
1999-02-16 |
Cell Genesys Inc. |
Packaging cell lines for adeno-associated viral vectors
|
US5714170A
(en)
|
1994-11-16 |
1998-02-03 |
Thomas Jefferson University |
Method of inducing resistance to tumor growth
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6638762B1
(en)
|
1994-11-28 |
2003-10-28 |
Genetic Therapy, Inc. |
Tissue-vectors specific replication and gene expression
|
FR2731710B1
(fr)
*
|
1995-03-14 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
|
WO1996028560A1
(fr)
*
|
1995-03-16 |
1996-09-19 |
Hisamitsu Pharmaceutical Co., Inc. |
Nouvelles souches cellulaires
|
FR2732357B1
(fr)
*
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
DE19513152A1
(de)
*
|
1995-04-07 |
1996-10-10 |
Bundesrep Deutschland |
Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren
|
US7745416B2
(en)
*
|
1995-04-11 |
2010-06-29 |
The Regents Of The University Of California |
Method for in vivo regulation of cardiac muscle contractility
|
US6638264B1
(en)
*
|
1995-05-16 |
2003-10-28 |
Biostratum Incorporation |
Perfusion apparatus and methods for pharmaceutical delivery
|
AU5658196A
(en)
*
|
1995-05-16 |
1996-11-29 |
Pirkko Heikkila |
Method for pharmaceutical delivery
|
JPH11505128A
(ja)
*
|
1995-05-22 |
1999-05-18 |
カイロン コーポレイション |
キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5990388A
(en)
*
|
1995-06-07 |
1999-11-23 |
Research Corporation Technologies, Inc. |
Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
US6110456A
(en)
*
|
1995-06-07 |
2000-08-29 |
Yale University |
Oral delivery or adeno-associated viral vectors
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
US5770720A
(en)
*
|
1995-08-30 |
1998-06-23 |
Barnes-Jewish Hospital |
Ubiquitin conjugating enzymes having transcriptional repressor activity
|
US5795872A
(en)
*
|
1995-09-19 |
1998-08-18 |
Pharmadigm, Inc. |
DNA construct for immunization
|
US6162796A
(en)
*
|
1995-09-27 |
2000-12-19 |
The Rockefeller University |
Method for transferring genes to the heart using AAV vectors
|
WO1997018241A1
(fr)
*
|
1995-11-14 |
1997-05-22 |
Thomas Jefferson University |
Methode pour provoquer une resistance a la croissance de tumeurs au moyen d'un recepteur de igf-1 soluble
|
SK70598A3
(en)
*
|
1995-11-30 |
1999-04-13 |
Univ Texas |
Methods and compositions for the diagnosis and treatment of cancer
|
CA2239733C
(fr)
|
1995-12-18 |
2001-04-03 |
Myriad Genetics, Inc. |
Gene de predisposition au cancer du sein lie au chromosome 13
|
US5837492A
(en)
|
1995-12-18 |
1998-11-17 |
Myriad Genetics, Inc. |
Chromosome 13-linked breast cancer susceptibility gene
|
EP0876491B1
(fr)
|
1995-12-22 |
2009-04-08 |
University Of Utah Research Foundation |
GENE DU SYNDROME DU Q-T LONG CODANT KVLQT1 ET SON ASSOCIATION AVEC minK
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
US5962313A
(en)
*
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
US5846528A
(en)
*
|
1996-01-18 |
1998-12-08 |
Avigen, Inc. |
Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
|
US5952221A
(en)
|
1996-03-06 |
1999-09-14 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a first and second nucleic acid sequence
|
DE19608751B4
(de)
*
|
1996-03-06 |
2006-05-18 |
Medigene Ag |
Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
|
GB9605124D0
(en)
|
1996-03-11 |
1996-05-08 |
Royal Free Hosp School Med |
Method of treating muscular disorders
|
US6723531B2
(en)
*
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
AU3130597A
(en)
|
1996-05-16 |
1997-12-05 |
Duke University |
Tristetraprolin
|
US6534314B1
(en)
|
1996-06-14 |
2003-03-18 |
Massachusetts Institute Of Technology |
Methods and compositions for transforming cells
|
US5928914A
(en)
*
|
1996-06-14 |
1999-07-27 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Methods and compositions for transforming cells
|
US5780447A
(en)
*
|
1996-06-14 |
1998-07-14 |
St. Jude Children's Research Hospital |
Recombinant adeno-associated viral vectors
|
WO1998000166A1
(fr)
|
1996-07-03 |
1998-01-08 |
Merial, Inc. |
ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
JP2001500376A
(ja)
|
1996-09-06 |
2001-01-16 |
カイロン コーポレイション |
組換えaavベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
|
AU4266597A
(en)
|
1996-09-11 |
1998-04-14 |
General Hospital Corporation, The |
Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
AU5070298A
(en)
*
|
1996-12-05 |
1998-06-29 |
Introgene B.V. |
Genetic modification of primate hemopoietic repopulating stem cells
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
GB9701425D0
(en)
*
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
US6218597B1
(en)
|
1997-04-03 |
2001-04-17 |
University Technology Corporation |
Transgenic model and treatment for heart disease
|
CA2288306A1
(fr)
|
1997-04-28 |
1998-11-05 |
Rhone-Poulenc Rorer S.A. |
Apport intratumoral, induit par un adenovirus, d'un antagoniste d'angiogenese destine au traitement de tumeurs
|
US6541036B1
(en)
|
1997-05-29 |
2003-04-01 |
Thomas Jefferson University |
Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
|
US6156303A
(en)
*
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
US20050096288A1
(en)
*
|
1997-06-13 |
2005-05-05 |
Aragene, Inc. |
Lipoproteins as nucleic acid vectors
|
US6635623B1
(en)
|
1997-06-13 |
2003-10-21 |
Baylor College Of Medicine |
Lipoproteins as nucleic acid vectors
|
GB9712512D0
(en)
|
1997-06-16 |
1997-08-20 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
US6300488B1
(en)
|
1997-07-10 |
2001-10-09 |
The Salk Institute For Biological Studies |
Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
WO1999018227A1
(fr)
*
|
1997-10-08 |
1999-04-15 |
Advanced Research And Technology Institute |
Systeme de vecteurs recombinants bases sur des parvovirus chimeres et specifiquement diriges sur le lignage erythrocitaire
|
US6346415B1
(en)
*
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
DE69835367T2
(de)
|
1997-10-29 |
2007-08-02 |
Genzyme Corp., Framingham |
Gentherapie für gaucher-krankheit
|
CA2671261A1
(fr)
|
1997-11-06 |
1999-05-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Antigenes de neisseria
|
US6512161B1
(en)
|
1998-01-08 |
2003-01-28 |
Aventis Pharmaceuticals, Inc. |
Transgenic rabbit that expresses a functional human lipoprotein (a)
|
US6780609B1
(en)
|
1998-10-23 |
2004-08-24 |
Genome Therapeutics Corporation |
High bone mass gene of 1.1q13.3
|
BR9906927A
(pt)
|
1998-01-14 |
2001-11-20 |
Chiron Spa |
Proteìnas de neisseria meningitidis
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
NZ541361A
(en)
|
1998-05-01 |
2008-04-30 |
Inst Genomic Research |
Neisseria meningitidis antigens and compositions relating to SEQ ID Nos:2916, 2918 and 2920
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6333318B1
(en)
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US7153655B2
(en)
*
|
1998-06-16 |
2006-12-26 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
|
US6135976A
(en)
|
1998-09-25 |
2000-10-24 |
Ekos Corporation |
Method, device and kit for performing gene therapy
|
US6743906B1
(en)
|
1998-10-02 |
2004-06-01 |
Board Of Regents, The University Of Texas |
PPP2R1B is a tumor suppressor
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US7129043B1
(en)
*
|
1998-10-22 |
2006-10-31 |
Duke University |
Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
US6855549B1
(en)
|
1998-11-23 |
2005-02-15 |
The University Of Iowa Research Foundation |
Methods and compositions for increasing the infectivity of gene transfer vectors
|
US6441156B1
(en)
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6495376B1
(en)
|
1999-02-18 |
2002-12-17 |
Beth Israel Deaconess Medical Center |
Methods and compositions for regulating protein-protein interactions
|
US7794703B1
(en)
*
|
1999-02-19 |
2010-09-14 |
Hai Xing Chen |
Method for production and delivery of a protein in vivo
|
US20030215423A1
(en)
*
|
1999-04-01 |
2003-11-20 |
Merck & Co., Inc. |
Gene therapy for obesity
|
US20080145347A1
(en)
*
|
1999-04-29 |
2008-06-19 |
Steiner Mitchell S |
p-Hyde sequences in the Rat
|
MXPA01010924A
(es)
|
1999-04-30 |
2002-05-06 |
Chiron Spa |
Antigenos de neisseria conservados.
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US6165754A
(en)
*
|
1999-06-08 |
2000-12-26 |
Cornell Research Foundation, Inc. |
Method of expressing an exogenous nucleic acid
|
US7504253B2
(en)
*
|
1999-06-11 |
2009-03-17 |
The Burnham Institute For Medical Research |
Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
DE60041542D1
(de)
|
1999-08-20 |
2009-03-26 |
Univ Texas |
Hdac4- und hdac5-abhängige regulation der genexpression im herzen
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
EP2275553B1
(fr)
|
1999-10-29 |
2015-05-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Peptides antigéniques de Neisseria
|
AU3642601A
(en)
*
|
1999-11-05 |
2001-05-30 |
Avigen, Inc. |
Ecdysone-inducible adeno-associated virus expression vectors
|
WO2001036603A2
(fr)
*
|
1999-11-17 |
2001-05-25 |
Avigen, Inc. |
Virions de virus adeno-associes recombinants destines au traitement de maladies lysosomales
|
AU1922101A
(en)
|
1999-11-18 |
2001-05-30 |
Chiron Corporation |
Human fgf-21 gene and gene expression products
|
US6241710B1
(en)
|
1999-12-20 |
2001-06-05 |
Tricardia Llc |
Hypodermic needle with weeping tip and method of use
|
ES2507100T3
(es)
|
2000-01-17 |
2014-10-14 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacuna OMV suplementada contra meningococo
|
EP1854476A3
(fr)
|
2000-02-09 |
2008-05-07 |
Bas Medical, Inc. |
Utilisation de la relaxine pour traiter des maladies associées à la vasoconstriction
|
JP4981229B2
(ja)
*
|
2000-02-25 |
2012-07-18 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
ハイブリッド血管内皮成長因子DNAsおよびタンパク質に関与する物質および方法
|
EP1261638A2
(fr)
|
2000-03-08 |
2002-12-04 |
Chiron Corporation |
Gene humain fgf-23 et produits d'expression associes
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
EP1950297A2
(fr)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
NZ560966A
(en)
|
2000-10-27 |
2010-06-25 |
Novartis Vaccines & Diagnostic |
Nucleic acids and proteins from streptococcus groups A & B
|
WO2002036761A2
(fr)
|
2000-11-03 |
2002-05-10 |
Dana Farber Cancer Institute |
Procedes et compositions pour le diagnostic des sensibilites aux cancers et mecanismes de reparation d'adn defectueux et traitement correspondant
|
US20030188326A1
(en)
|
2000-11-03 |
2003-10-02 |
Dana Farber Cancer Institute |
Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
|
US6958213B2
(en)
|
2000-12-12 |
2005-10-25 |
Alligator Bioscience Ab |
Method for in vitro molecular evolution of protein function
|
US20020086292A1
(en)
|
2000-12-22 |
2002-07-04 |
Shigeaki Harayama |
Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
|
MXPA03005386A
(es)
|
2000-12-28 |
2004-04-20 |
Wyeth Corp |
Proteina protectora recombinante de streptococcus pneumoniae.
|
US6613534B2
(en)
|
2001-03-20 |
2003-09-02 |
Wake Forest University Health Sciences |
MAP-2 as a determinant of metastatic potential
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002303247B2
(en)
*
|
2001-04-06 |
2005-03-24 |
Dana-Farber Cancer Institute |
Chemotherapeutic induction of Egr-1 promoter activity
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
WO2002081641A2
(fr)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
WO2002081639A2
(fr)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 et ses utilisations diagnostiques et therapeutiques
|
WO2002097056A2
(fr)
*
|
2001-05-31 |
2002-12-05 |
The Rockefeller University |
Methode de generation de vecteurs viraux defectifs pour la replication exempts de virus assistant
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
WO2003002746A2
(fr)
*
|
2001-06-29 |
2003-01-09 |
Novartis Ag |
Methode de criblage de perv et son utilisation
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
KR100982204B1
(ko)
|
2001-12-12 |
2010-09-14 |
노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. |
클라미디아 트라코마티스에 대한 면역화
|
MXPA04008890A
(es)
|
2002-03-15 |
2005-10-18 |
Wyeth Corp |
Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
|
US7384738B2
(en)
*
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
JP5578388B2
(ja)
|
2002-04-18 |
2014-08-27 |
オプコ ファーマシューティカルズ、エルエルシー |
中枢神経システム及び/若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法
|
WO2003097834A2
(fr)
*
|
2002-05-17 |
2003-11-27 |
Alligator Bioscience Ab |
Methode de developpement moleculaire in vitro d'une fonction de proteine
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
AU2003291433B2
(en)
|
2002-11-13 |
2008-05-22 |
Thomas Jefferson University |
Compositions and methods for cancer diagnosis and therapy
|
ES2347239T3
(es)
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
US20050048041A1
(en)
*
|
2003-01-13 |
2005-03-03 |
Rao Mahendra S. |
Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
|
ATE477337T1
(de)
|
2003-01-16 |
2010-08-15 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US20050028229A1
(en)
*
|
2003-04-14 |
2005-02-03 |
Mitchell Weiss |
Alpha-hemoglobin stabilizing protein transgenic mouse and methods of use thereof
|
AU2003241006B2
(en)
*
|
2003-05-21 |
2011-03-24 |
Ares Trading S.A. |
TNF-like secreted protein
|
CA2538843A1
(fr)
*
|
2003-09-12 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Modele animal permettant d'etudier l'activite des proteases et les atteintes hepatiques
|
US20060078558A1
(en)
*
|
2003-11-12 |
2006-04-13 |
Whitsett Jeffrey A |
Diagnosis, prognosis and treatment of pulmonary diseases
|
WO2005054438A2
(fr)
|
2003-12-01 |
2005-06-16 |
Invitrogen Corporation |
Molecule d'acide nucleique contenant des sites de recombinaison et leurs procedes d'utilisation
|
WO2005067708A2
(fr)
|
2004-01-14 |
2005-07-28 |
Daniolabs Limited |
Modeles d'animaux et utilisations de ceux-ci
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
EP2295604B1
(fr)
|
2004-02-09 |
2015-04-08 |
Thomas Jefferson University |
Diagnostic et traitement de cancers à l'aide de microARN présent dans ou au voisinage de caractéristiques chromosomiques associées aux cancers
|
WO2005087808A2
(fr)
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Matieres et procedes de constructions de liaison de facteurs de croissance
|
ES2423060T3
(es)
*
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
US7582442B2
(en)
*
|
2004-03-16 |
2009-09-01 |
The Regents Of The University Of Michigan |
Methods and compositions for using aleveolar macrophage phospholipase A2
|
US7319015B2
(en)
*
|
2004-03-16 |
2008-01-15 |
The Regents Of The University Of Michigan |
Methods and compositions for using alveolar macrophage phospholipase A2
|
DK1736541T3
(da)
|
2004-03-29 |
2013-05-06 |
Galpharma Co Ltd |
Nyt modificeret galectin 9-protein og anvendelse heraf
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
WO2006014798A2
(fr)
*
|
2004-07-27 |
2006-02-09 |
Mount Sinai School Of Medicine |
Procedes et compositions pour l'utilisation de sax2
|
WO2006026348A1
(fr)
*
|
2004-08-25 |
2006-03-09 |
The University Of Chicago |
Utilisation d'une combinaison comprenant du temozolomide et un tnf-alpha pour le traitement d'un glioblastome
|
FI20050753A
(fi)
|
2004-09-03 |
2006-03-04 |
Licentia Oy |
Uudet peptidit
|
GB0423126D0
(en)
*
|
2004-10-18 |
2004-11-17 |
Ares Trading Sa |
Protein
|
WO2006055635A2
(fr)
*
|
2004-11-15 |
2006-05-26 |
Mount Sinai School Of Medicine Of New York University |
Compositions et methodes de modification de la signalisation autocrine wnt
|
GB0426960D0
(en)
*
|
2004-12-08 |
2005-01-12 |
Ares Trading Sa |
TGR-3 like protein receptor
|
US7531523B2
(en)
*
|
2005-02-17 |
2009-05-12 |
Vertex Pharmaceuticals Incorporated |
Sodium channel protein type III alpha-subunit splice variant
|
GB0504767D0
(en)
*
|
2005-03-08 |
2005-04-13 |
Ares Trading Sa |
Lipocalin protein
|
WO2006099574A2
(fr)
*
|
2005-03-16 |
2006-09-21 |
Tai June Yoo |
Systemes d'expression et de diffusion genetiques d'allergenes de blattes
|
WO2006102643A2
(fr)
*
|
2005-03-24 |
2006-09-28 |
Caritas St. Elizabeth Medical Center Boston, Inc. |
Cellules de moelle osseuse transformees de maniere stable et utilisations de ces dernieres
|
KR20080025373A
(ko)
|
2005-05-17 |
2008-03-20 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법
|
EP1907855A4
(fr)
*
|
2005-07-12 |
2009-11-11 |
Univ Temple |
Modifications génétiques et épigénétiques dans le diagnostic et le traitement du cancer
|
WO2007016643A2
(fr)
*
|
2005-08-01 |
2007-02-08 |
Mount Sinai School Of Medicine Of New York University |
Procédé visant à prolonger la longévité au moyen d’antagonistes de npc1l1
|
EP2594591B1
(fr)
|
2005-08-11 |
2018-06-06 |
Arpi Matossian-Rogers |
Peptides associés au tcr-v beta pour traitement et diagnostic d'une maladie auto-immune
|
WO2007022287A2
(fr)
|
2005-08-15 |
2007-02-22 |
Vegenics Limited |
Vegf-a modifié aux propriétés angiogéniques améliorées
|
ES2523989T3
(es)
|
2005-09-12 |
2014-12-03 |
The Ohio State University Research Foundation |
Composiciones para la terapia de cánceres asociados con BCL2
|
US20080200408A1
(en)
*
|
2005-09-30 |
2008-08-21 |
Mccormack Kenneth |
Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
|
US7972813B2
(en)
*
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
GB2432366B
(en)
*
|
2005-11-19 |
2007-11-21 |
Alligator Bioscience Ab |
A method for in vitro molecular evolution of protein function
|
CA2524619A1
(fr)
*
|
2005-11-22 |
2007-05-22 |
Ottawa Health Research Institute |
Nouvelles cellules souches, sequences nucleotides et proteines provenant de celles-ci
|
PL1969003T3
(pl)
|
2005-12-14 |
2011-05-31 |
Herantis Pharma Plc |
Zastosowanie białka czynnika neurotroficznego
|
EP1966379B1
(fr)
*
|
2005-12-22 |
2010-04-28 |
OPKO Ophthalmics, LLC |
Compositions et procédés pour réguler le système du complément
|
WO2007123579A2
(fr)
|
2005-12-28 |
2007-11-01 |
Translational Therapeutics |
Thérapeutique reposant sur une perturbation de traduction
|
CN102943108B
(zh)
|
2006-01-05 |
2014-05-21 |
俄亥俄州立大学研究基金会 |
用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
|
EP1968622B1
(fr)
|
2006-01-05 |
2014-08-27 |
The Ohio State University Research Foundation |
Anomalies dans l'expression des micro-arn dans des tumeurs endocrines pancréatiques et des tumeurs à cellules acineuses
|
ES2461189T3
(es)
|
2006-01-05 |
2014-05-19 |
The Ohio State University Research Foundation |
Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
|
US8229398B2
(en)
*
|
2006-01-30 |
2012-07-24 |
Qualcomm Incorporated |
GSM authentication in a CDMA network
|
US20090214496A1
(en)
*
|
2006-01-30 |
2009-08-27 |
Licentia Ltd. |
Bmx/etk tyrosine kinase gene therapy materials and methods
|
EP2522750A1
(fr)
|
2006-03-02 |
2012-11-14 |
The Ohio State University |
Profil d'expression de micro-ARN associé au cancer du pancréas
|
EP2311477B1
(fr)
|
2006-03-20 |
2014-07-09 |
Japan Science and Technology Agency |
Utilisation de ip3-réceptor-binding- protein pour le contrôle du métabolisme phosphatidylinositol
|
EP2369012A1
(fr)
|
2006-03-20 |
2011-09-28 |
The Ohio State University Research Foundation |
Empreintes digitales micro-ARN pendant une mégacaryocytopoïese
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
EP2065463A3
(fr)
|
2006-04-07 |
2009-09-02 |
Neuro Therapeutics AB |
Survie et développement des cellules nerveuses
|
US7691824B2
(en)
*
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
US7723564B2
(en)
|
2006-05-10 |
2010-05-25 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for modulation of KSR1 and KSR2 interactions
|
EP3578656B1
(fr)
|
2006-05-11 |
2021-01-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition d'expression du gène pcsk9
|
WO2007136679A2
(fr)
|
2006-05-17 |
2007-11-29 |
Ludwig Institute For Cancer Research |
Cibler la régulation du vegf-b des transporteurs d'acides gras afin de moduler les maladies humaines
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
AU2007253677B2
(en)
|
2006-05-22 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
EP2035035A2
(fr)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Compositions immunogenes pour streptococcus agalactiae
|
US20080152654A1
(en)
*
|
2006-06-12 |
2008-06-26 |
Exegenics, Inc., D/B/A Opko Health, Inc. |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
|
ES2425387T3
(es)
|
2006-07-13 |
2013-10-15 |
The Ohio State University Research Foundation |
Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
|
EP2049666A2
(fr)
|
2006-07-28 |
2009-04-22 |
Sanofi-Aventis |
Composition et procédé pour le traitement de tumeurs
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
ES2388567T3
(es)
|
2006-10-19 |
2012-10-16 |
Csl Limited |
Anticuerpos anti-il-13r alfa 1 y usos de los mismos
|
ES2501947T3
(es)
|
2006-10-19 |
2014-10-02 |
Csl Limited |
Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
|
US20080113915A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Duke University |
SAPAP3 knockout mouse and clinical modeling associated with the SAPAP3 gene
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
NZ579050A
(en)
*
|
2007-02-06 |
2012-10-26 |
Tai June Yoo |
Treatment and prevention of neurodegenerative diseases using gene therapy
|
WO2008115387A2
(fr)
*
|
2007-03-15 |
2008-09-25 |
University Hospitals Of Cleveland |
Criblage, diagnostic, traitement et pronostic d'états pathophysiologiques par régulation d'arn
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
EP2905336A1
(fr)
|
2007-03-29 |
2015-08-12 |
Alnylam Pharmaceuticals Inc. |
Compositions et procédés pour inhiber l'expression d'un gène à partir du virus Ébola
|
AU2008270209B2
(en)
|
2007-07-05 |
2012-05-17 |
Arrowhead Pharmaceuticals, Inc. |
dsRNA for treating viral infection
|
WO2009012263A2
(fr)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn
|
CN101809169B
(zh)
|
2007-07-31 |
2013-07-17 |
俄亥俄州立大学研究基金会 |
通过靶向dnmt3a和dnmt3b恢复甲基化的方法
|
ES2627059T3
(es)
|
2007-08-03 |
2017-07-26 |
The Ohio State University Research Foundation |
Regiones ultraconservadas que codifican ARNnc
|
JP5770472B2
(ja)
|
2007-08-22 |
2015-08-26 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションThe Ohio State University Research Foundation |
ヒト急性白血病におけるepha7及びerkリン酸化の調節解除を誘発するための方法及び組成物
|
CN101939446B
(zh)
|
2007-09-06 |
2015-02-11 |
俄亥俄州立大学研究基金会 |
人类卵巢癌中的微小rna特征
|
AU2008310704B2
(en)
|
2007-10-11 |
2014-03-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
|
FI20070808A0
(fi)
|
2007-10-25 |
2007-10-25 |
Mart Saarma |
GDNF:n silmukointivariantit ja niiden käytöt
|
CA2707042A1
(fr)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procedes permettant l'inhibition de l'expression du gene du facteur vii
|
US20090196854A1
(en)
*
|
2008-02-04 |
2009-08-06 |
Kytos Biosystems S.A. |
Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
|
JP2011518117A
(ja)
|
2008-03-05 |
2011-06-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Eg5およびVEGF遺伝子の発現を阻害するための組成物および方法
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
WO2010002895A2
(fr)
|
2008-06-30 |
2010-01-07 |
The Regents Of The University Of Michigan |
Activité phospholipase a2 lysosomale (lpla2) en tant que cible diagnostique et thérapeutique pour identifier et traiter le lupus érythémateux disséminé
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
CA2739170A1
(fr)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions a base de preparation lipidique et methodes destinees a inhiber l'expression d'un gene de serum amyloide a
|
EP2344639B1
(fr)
|
2008-10-20 |
2015-04-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés pour inhiber l'expression de la transthyrétine
|
KR20110081282A
(ko)
|
2008-11-05 |
2011-07-13 |
와이어쓰 엘엘씨 |
베타―용혈성 연쇄구균 (bhs) 질환의 예방을 위한 다성분 면역원성 조성물
|
EP2361306A1
(fr)
|
2008-12-04 |
2011-08-31 |
OPKO Ophthalmics, LLC |
Compositions et procédés pour l'inhibition sélective d'isoformes pro-angiogéniques de vegf
|
NZ593618A
(en)
|
2008-12-10 |
2013-02-22 |
Alnylam Pharmaceuticals Inc |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
JP6032724B2
(ja)
|
2009-03-12 |
2016-11-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法
|
CA2755870C
(fr)
|
2009-03-20 |
2019-04-09 |
Angioblast Systems, Inc. |
Production de cellules pluripotentes reprogrammees
|
CA2993053A1
(fr)
|
2009-04-27 |
2010-11-04 |
Novartis Ag |
Anticorps anti-recepteur de l'activine iib (actriib) destines a augmenter la croissance musculaire
|
CN102639151B
(zh)
*
|
2009-05-01 |
2017-03-22 |
库尔纳公司 |
通过针对hbf/hbg的天然反义转录物的抑制治疗血红蛋白(hbf/hbg)相关疾病
|
GB0908425D0
(en)
|
2009-05-15 |
2009-06-24 |
Medical Res Council |
Medical use
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
AP2015008874A0
(en)
|
2009-08-14 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
CA2778678A1
(fr)
|
2009-10-30 |
2011-05-05 |
Cns Therapeutics, Inc. |
Molecules de neurturine ameliorees
|
CN105031618A
(zh)
|
2009-11-02 |
2015-11-11 |
加利福尼亚大学董事会 |
用于细胞因子递送的穹窿体复合物
|
US8551781B2
(en)
|
2009-11-19 |
2013-10-08 |
The Regents Of The University Of California |
Vault complexes for facilitating biomolecule delivery
|
CA2782728A1
(fr)
*
|
2009-12-04 |
2011-06-09 |
Opko Ophthalmics, Llc |
Compositions et procedes d'inhibition de vegf
|
JP5860029B2
(ja)
|
2010-03-29 |
2016-02-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチン(TTR)関連眼アミロイドーシスのためのsiRNA療法
|
EP2563907B1
(fr)
|
2010-04-28 |
2019-06-19 |
The J. David Gladstone Institutes |
Procédés de génération de cardiomyocytes
|
EP3078753B1
(fr)
|
2010-05-10 |
2018-04-18 |
The Regents of The University of California |
Procédés utilisant des compositions d'endoribonucléases
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
EP2580328A2
(fr)
|
2010-06-11 |
2013-04-17 |
Cellartis AB |
Microarn pour la détection et l'isolement de types cellulaires cardiaques dérivés de cellules souches embryonnaires humaines
|
US9011863B2
(en)
|
2010-07-09 |
2015-04-21 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
GB201012651D0
(en)
|
2010-07-28 |
2010-09-15 |
Univ Edinburgh |
Peptides
|
PT3246044T
(pt)
|
2010-08-23 |
2021-02-15 |
Wyeth Llc |
Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
|
NZ607224A
(en)
|
2010-09-10 |
2014-11-28 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
EP2627349B1
(fr)
|
2010-10-15 |
2016-02-03 |
The Trustees of Columbia University in the City of New York |
Gènes de l'obésité, leurs protéines et leurs utilisations
|
PL2635299T3
(pl)
|
2010-11-02 |
2020-03-31 |
The Trustees Of Columbia University In The City Of New York |
Sposoby leczenia zaburzeń utraty włosów
|
CN103492564B
(zh)
|
2010-11-05 |
2017-04-19 |
斯坦福大学托管董事会 |
光活化嵌合视蛋白及其使用方法
|
EP3225108A1
(fr)
|
2010-11-05 |
2017-10-04 |
The Board of Trustees of The Leland Stanford Junior University |
Régulation optogénétique de comportements associés au système de récompense
|
US9198975B2
(en)
|
2010-12-01 |
2015-12-01 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeting sites of neovascular growth
|
WO2012078967A2
(fr)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés pour l'augmentation de la production d'érythropoïétine (epo)
|
EP2648763A4
(fr)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Compositions et procédés d'inhibition de l'expression des gènes klf-1 et bcl11a
|
WO2012109495A1
(fr)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cibles cellulaires de thiazolidinediones
|
SG193923A1
(en)
|
2011-03-29 |
2013-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene
|
WO2012142526A1
(fr)
|
2011-04-14 |
2012-10-18 |
Modiano Jaime |
Utilisation de l'expression tumorale de fas pour déterminer la réponse à une thérapie anticancéreuse
|
EP3623381A1
(fr)
|
2011-05-19 |
2020-03-18 |
The Regents Of The University Of Michigan |
Agents de liaison d'intégrine alpha-2 et son utilisation pour inhiber la prolifération de cellules cancéreuses
|
WO2012164058A1
(fr)
|
2011-06-01 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés pour l'ajustement de l'expression du génome mitochondrial par un microarn
|
AU2012272908A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
MX360782B
(es)
|
2011-06-21 |
2018-11-16 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni similares a angiopoyetina 3 (angptl3) y metodos para su uso.
|
MX344807B
(es)
|
2011-06-21 |
2017-01-09 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de genes para alipoproteina c-iii (apoc3).
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
EP3366312A1
(fr)
|
2011-06-23 |
2018-08-29 |
Alnylam Pharmaceuticals, Inc. |
Arnsi de serpina 1 : compositions de matière et procédés de traitement
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
CN103998057A
(zh)
|
2011-09-15 |
2014-08-20 |
美国加州大学洛杉矶海滨分校医学中心的洛杉矶生物医学研究所 |
利用CotH的毛霉菌病的免疫疗法和诊断
|
JP2014530612A
(ja)
|
2011-10-14 |
2014-11-20 |
ジ・オハイオ・ステート・ユニバーシティ |
卵巣がんに関する方法および材料
|
EP2771482A1
(fr)
|
2011-10-27 |
2014-09-03 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Méthodes pour le traitement et le diagnostic de l'athérosclérose
|
US9265813B2
(en)
|
2011-10-27 |
2016-02-23 |
Wellstat Ophthalmics Corporation |
Vectors encoding rod-derived cone viability factor
|
US9365496B2
(en)
|
2011-11-30 |
2016-06-14 |
Ludwig Institute For Cancer Research |
iNKT cell modulators and methods of using the same
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
CN104093833B
(zh)
|
2011-12-16 |
2017-11-07 |
斯坦福大学托管董事会 |
视蛋白多肽及其使用方法
|
EP2814514B1
(fr)
|
2012-02-16 |
2017-09-13 |
Atyr Pharma, Inc. |
Histidyl-arnt synthétases pour le traitement de maladies auto-immunes et inflammatoires
|
WO2013126521A1
(fr)
|
2012-02-21 |
2013-08-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions et méthodes destinées à traiter les troubles neurogènes du plancher pelvien
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
NZ628449A
(en)
|
2012-03-09 |
2016-04-29 |
Pfizer |
Neisseria meningitidis compositions and methods thereof
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
ES2694681T3
(es)
|
2012-03-29 |
2018-12-26 |
The Trustees Of Columbia University In The City Of New York |
Métodos para tratar trastornos de pérdida capilar
|
WO2013152230A1
(fr)
|
2012-04-04 |
2013-10-10 |
The Trustees Of Columbia University In The City Of New York |
Inhibition spécifique des muscles lisses dans le cadre d'une thérapie anti-resténosique
|
JP2015518475A
(ja)
|
2012-04-10 |
2015-07-02 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) |
非アルコール性脂肪性肝炎の治療方法
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
WO2013153139A1
(fr)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes pour le traitement et le diagnostic de la leucémie aiguë
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
PE20150336A1
(es)
|
2012-05-25 |
2015-03-25 |
Univ California |
Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
|
WO2013184209A1
(fr)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif destiné à être utilisé dans des méthodes de traitement de sujets atteints d'une maladie neurodégénérative
|
WO2014011705A1
(fr)
|
2012-07-09 |
2014-01-16 |
The Regents Of The University Of California |
Immunothérapie de voûte
|
EP3539563A1
(fr)
|
2012-07-19 |
2019-09-18 |
Redwood Bioscience, Inc. |
Anticorps spécifique pour cd22 et ses procédés d'utilisation
|
US20140037599A1
(en)
*
|
2012-08-03 |
2014-02-06 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods of Treating T Cell Deficiency
|
ME03667B
(fr)
|
2012-08-16 |
2020-10-20 |
Ipierian Inc |
Méthodes de traitement d'une tauopathie
|
WO2014039916A1
(fr)
|
2012-09-06 |
2014-03-13 |
The University Of Chicago |
Polynucléotides antisens destinés à induire un saut d'exon et méthodes de traitement de dystrophies
|
JP6538561B2
(ja)
|
2012-10-25 |
2019-07-03 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
抗補体C1s抗体とそれらの用途
|
CA2889197A1
(fr)
|
2012-11-02 |
2014-05-08 |
True North Therapeutics, Inc. |
Anticorps anti-complement c1s et utilisations de ceux-ci
|
JP6580487B2
(ja)
|
2012-11-21 |
2019-09-25 |
サーキット セラピューティクス, インコーポレイテッド |
光遺伝学的治療のためのシステムおよび方法
|
RS56783B9
(sr)
|
2012-12-05 |
2021-12-31 |
Alnylam Pharmaceuticals Inc |
Sastavi pcsk9 irnk i postupci njihovih primena
|
WO2014127148A1
(fr)
|
2013-02-14 |
2014-08-21 |
The J. David Gladstone Institutes |
Compositions et procédés d'utilisation de celles-ci pour identifier des agents antiviraux
|
JP6450690B2
(ja)
|
2013-02-15 |
2019-01-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
キメラ抗原受容体及びその使用方法
|
SI2956476T1
(sl)
|
2013-02-18 |
2020-03-31 |
Vegenics Pty Limited |
Molekule za vezavo na ligande in uporabe le-teh
|
US9802987B2
(en)
|
2013-03-08 |
2017-10-31 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
EP2968613B1
(fr)
|
2013-03-11 |
2019-09-11 |
University of Florida Research Foundation, Inc. |
Délivrance d'une protéine card en tant que thérapie pour inflammation oculaire
|
JP6431035B2
(ja)
|
2013-03-13 |
2018-11-28 |
ジーンウィーブ バイオサイエンシズ,インコーポレイティド |
非複製的形質導入粒子及び形質導入粒子に基づくレポーターシステム
|
US9481903B2
(en)
|
2013-03-13 |
2016-11-01 |
Roche Molecular Systems, Inc. |
Systems and methods for detection of cells using engineered transduction particles
|
AU2014244116B9
(en)
|
2013-03-14 |
2020-08-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component C5 iRNA compositions and methods of use thereof
|
WO2014151734A1
(fr)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Protéines de fusion et procédés correspondants
|
CN105246550A
(zh)
|
2013-03-15 |
2016-01-13 |
小利兰·斯坦福大学托管委员会 |
行为状态的光遗传学控制
|
CA2918194C
(fr)
|
2013-03-27 |
2022-12-06 |
The General Hospital Corporation |
Procedes et agents pour le traitement de la maladie d'alzheimer
|
JP6549559B2
(ja)
|
2013-04-29 |
2019-07-24 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
|
TWI664187B
(zh)
|
2013-05-22 |
2019-07-01 |
阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
AP2015008862A0
(en)
|
2013-05-22 |
2015-11-30 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
WO2014191630A2
(fr)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Modèle animal non humain codant pour un gène manf non fonctionnel
|
WO2014193632A2
(fr)
|
2013-05-29 |
2014-12-04 |
Vybion, Inc. |
Intracorps à chaîne unique modifiant la dégradation de la protéine mutante huntingtin
|
US9951114B2
(en)
|
2013-06-04 |
2018-04-24 |
Virginia Commonwealth University |
Recombinant cancer therapeutic cytokine
|
WO2014197599A1
(fr)
|
2013-06-04 |
2014-12-11 |
The Johns Hopkins University |
Expression en surface de l'avidine/streptavidine, médiée par peg-prom
|
US9750823B2
(en)
|
2013-06-04 |
2017-09-05 |
Virginia Commonwealth University |
Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics
|
EP3004872B1
(fr)
|
2013-06-04 |
2017-10-18 |
Virginia Commonwealth University |
Promoteur du gène de la synténine (mda-9) utilisé pour la prise d'image et le traitement de cellules cancéreuses métastatiques
|
US10166300B2
(en)
|
2013-06-04 |
2019-01-01 |
Virginia Commonwealth University |
Tripartite cancer theranostic nucleic acid constructs
|
CN105339002B
(zh)
|
2013-06-10 |
2019-06-28 |
伊皮埃里安股份有限公司 |
治疗tau病变的方法
|
CA2916533C
(fr)
|
2013-06-25 |
2022-12-20 |
University Of Canberra |
Procedes et compositions de modulation des cellules souches cancereuses
|
WO2015023782A1
(fr)
|
2013-08-14 |
2015-02-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions et procédés pour réguler une douleur
|
EP4098276A1
(fr)
|
2013-09-08 |
2022-12-07 |
Pfizer Inc. |
Compositions utilisables contre neisseria meningitidis et procédés associés
|
SG11201601408PA
(en)
|
2013-09-18 |
2016-04-28 |
Univ Canberra |
Stem cell modulation ii
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
MY197646A
(en)
|
2013-10-04 |
2023-06-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of the alas1 gene
|
CA2930877A1
(fr)
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Systeme crips-cas, materiels et procedes
|
WO2015086828A1
(fr)
|
2013-12-12 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Procédés pour la prévention et le traitement de la cardiomyopathie diabétique à l'aide de mir-424/322
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
US9994831B2
(en)
|
2013-12-12 |
2018-06-12 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
KR102592370B1
(ko)
|
2014-02-11 |
2023-10-25 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법
|
WO2015127094A1
(fr)
|
2014-02-19 |
2015-08-27 |
University Of Florida Research Foundation, Inc. |
Administration de nrf2 en tant que thérapie de protection contre les dérivés réactifs de l'oxygène
|
EP3122761B1
(fr)
|
2014-03-28 |
2019-03-06 |
The Board of Trustees of The Leland Stanford Junior University |
Protéines de canal anionique manipulées activées par la lumière et procédés d'utilisation de celles-ci
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
KR102410687B1
(ko)
|
2014-05-22 |
2022-06-22 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) irna 조성물 및 이의 사용 방법
|
WO2015191508A1
(fr)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Capsides chimériques
|
EP3480213B1
(fr)
|
2014-06-18 |
2019-11-13 |
Albert Einstein College of Medicine |
Polypeptides syntac et leurs utilisations
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
JP2017525377A
(ja)
|
2014-08-25 |
2017-09-07 |
ジーンウィーブ バイオサイエンシズ,インコーポレイティド |
非複製的形質導入粒子及び形質導入粒子に基づくレポーターシステム
|
JP2017528452A
(ja)
|
2014-08-25 |
2017-09-28 |
ユニバーシティ・オブ・キャンベラUniversity of Canberra |
がん幹細胞を調節するための組成物およびその使用
|
CN107073091A
(zh)
|
2014-09-07 |
2017-08-18 |
西莱克塔生物科技公司 |
用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
|
BR112017005892A2
(pt)
|
2014-09-24 |
2017-12-12 |
Hope City |
variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
JP6863891B2
(ja)
|
2014-11-14 |
2021-04-21 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. |
調節性ポリヌクレオチド
|
IL292999A
(en)
|
2014-11-14 |
2022-07-01 |
Voyager Therapeutics Inc |
Preparations and methods for the treatment of amyotrophic lateral sclerosis
|
WO2016081444A1
(fr)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni d'apolipoprotéine c3 (apoc3) et procédés d'utilisation de ces compositions
|
WO2016094783A1
(fr)
|
2014-12-12 |
2016-06-16 |
Voyager Therapeutics, Inc. |
Compositions et méthodes pour la production de scaav
|
WO2016105517A1
(fr)
|
2014-12-23 |
2016-06-30 |
The Trustees Of Columbia University In The City Of New York |
Protéines de fusion et procédés associés
|
CA2976445A1
(fr)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni du gene codant pour la proteine 3 contenant un domaine phospholipase de type patatine (pnpla3) et leurs procedes d'utilisation
|
KR20170103009A
(ko)
|
2015-02-19 |
2017-09-12 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
WO2016148994A1
(fr)
|
2015-03-13 |
2016-09-22 |
The Jackson Laboratory |
Système de complexe cas/crispr à trois constituants et utilisations de ce dernier
|
EP3280440B1
(fr)
|
2015-04-06 |
2022-11-16 |
Bioverativ USA Inc. |
Anticorps anti-c1s humanisés et leurs procédés d'utilisation
|
EP3280425B1
(fr)
|
2015-04-07 |
2022-06-01 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Méthodes pour induire la division cellulaire de cellules post-mitotiques
|
EP3283500B1
(fr)
|
2015-04-08 |
2020-11-11 |
The University of Chicago |
Compositions et méthodes de correction de la dystrophie musculaire des ceintures de type 2c par saut d'exon
|
US10729790B2
(en)
|
2015-05-26 |
2020-08-04 |
Salk Institute For Biological Studies |
Motor neuron-specific expression vectors
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
WO2016201301A1
(fr)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation
|
US11273167B2
(en)
|
2015-08-03 |
2022-03-15 |
The Regents Of The University Of California |
Compositions and methods for modulating ABHD2 activity
|
ES2842306T3
(es)
|
2015-09-02 |
2021-07-13 |
Immutep Sas |
Anticuerpos anti LAG-3
|
EP3347486A4
(fr)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
|
EP3353297A1
(fr)
|
2015-09-24 |
2018-08-01 |
Crispr Therapeutics AG |
Nouvelle famille d'endonucléases arn-programmables et leurs utilisations dans l'édition de génome et d'autres applications
|
US10188750B1
(en)
|
2015-10-23 |
2019-01-29 |
University Of South Florida |
Self-replicating cell selective gene delivery compositions, methods, and uses thereof
|
CA3006569A1
(fr)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Dosages pour la detection d'anticorps neutralisants de vaa
|
SG11201804038VA
(en)
|
2016-01-08 |
2018-06-28 |
Univ California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
EP3416726A4
(fr)
|
2016-02-17 |
2019-08-28 |
Children's Medical Center Corporation |
Ffa1 (gpr40) utilisé comme cible thérapeutique pour des maladies ou des troubles neuronaux liés à l'angiogenèse
|
KR20180132070A
(ko)
|
2016-03-03 |
2018-12-11 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
WO2020047527A2
(fr)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Procédés et compositions pour modifier génétiquement des lymphocytes dans le sang ou dans des pbmc enrichies
|
CN108884460B
(zh)
|
2016-03-19 |
2023-04-28 |
埃克苏马生物技术公司 |
淋巴细胞转导及其扩增调节的方法与组合物
|
PE20190209A1
(es)
|
2016-04-04 |
2019-02-07 |
Bioverativ Usa Inc |
Anticuerpos anti-factor bb del complemento y uso de estos
|
US20190145961A1
(en)
|
2016-04-20 |
2019-05-16 |
Washington University |
Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics Inc |
composições e métodos de tratamento da doença de huntington
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
KR20190019068A
(ko)
|
2016-05-18 |
2019-02-26 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
IL262606B2
(en)
|
2016-05-18 |
2023-04-01 |
Albert Einstein College Medicine Inc |
pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
|
EP3469083A1
(fr)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni du composant c5 du complément et leurs méthodes d'utilisation pour traiter l'hémoglobinurie paroxystique nocturne (hpn)
|
AU2017292936C1
(en)
|
2016-07-08 |
2024-05-02 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
CA3035522A1
(fr)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Procedes de ciblage et d'administration biomedicaux, et dispositifs et systemes pour la mise en uvre de ceux-ci
|
JP7063885B2
(ja)
|
2016-09-13 |
2022-05-09 |
ザ ジャクソン ラボラトリー |
標的にされた増大するdna脱メチル化
|
WO2018057648A1
(fr)
|
2016-09-20 |
2018-03-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Régulateurs peptidiques de la fusion mitochondriale et procédés d'utilisation
|
EP3299460A1
(fr)
|
2016-09-26 |
2018-03-28 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Nouveaux composes et procedes destines a moduler l'expression de l'ubiquitination
|
AR110677A1
(es)
|
2016-10-12 |
2019-04-24 |
Bioverativ Usa Inc |
Anticuerpos anti-c1s y métodos para usarlos
|
US11154591B2
(en)
|
2016-10-14 |
2021-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
AU2017376950B2
(en)
|
2016-12-16 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions
|
DK3558339T3
(da)
|
2016-12-22 |
2024-02-26 |
Cue Biopharma Inc |
T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
|
WO2018129474A1
(fr)
|
2017-01-09 |
2018-07-12 |
Cue Biopharma, Inc. |
Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
|
EP3571229A1
(fr)
|
2017-01-18 |
2019-11-27 |
F1 Oncology, Inc. |
Récepteurs antigéniques chimériques contre axl ou ror2 et procédés d'utilisation associés
|
CN110234756A
(zh)
|
2017-01-18 |
2019-09-13 |
F1肿瘤医学公司 |
转导和扩增免疫细胞的方法及其用途
|
CN118021947A
(zh)
|
2017-01-31 |
2024-05-14 |
辉瑞大药厂 |
脑膜炎奈瑟菌组合物及其使用方法
|
CA3054064A1
(fr)
|
2017-03-03 |
2018-09-07 |
F1 Oncology, Inc. |
Procedes et compositions pour la transduction et l'expansion de lymphocytes et la regulation de l'activite de ces derniers
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
AU2018261790A1
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
US11497576B2
(en)
|
2017-07-17 |
2022-11-15 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
JP7221275B2
(ja)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Aavを送達するための組成物および方法
|
WO2019051127A1
(fr)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
Polypeptide multimère modulateur de lymphocyte t ayant des sites de conjugaison et procédés d'utilisation associés
|
AU2018328291B2
(en)
|
2017-09-08 |
2022-10-27 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
JP2020534811A
(ja)
|
2017-09-08 |
2020-12-03 |
マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. |
Fc領域を含有する条件的に活性化された結合部分
|
US11485957B2
(en)
|
2017-10-10 |
2022-11-01 |
Nantbio, Inc. |
Modified EC7 cells having low toxicity to viral production payloads
|
CN111527105A
(zh)
|
2017-10-11 |
2020-08-11 |
美国比奥维拉迪维股份有限公司 |
诱导补体活性的方法
|
WO2019079240A1
(fr)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
Traitement de la sclérose latérale amyotrophique (sla)
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
KR20200095462A
(ko)
*
|
2017-10-18 |
2020-08-10 |
시티 오브 호프 |
Hbb 유전자 기능 회복을 위한 아데노-연관 바이러스 조성물 및 이의 사용 방법
|
EP3704252A1
(fr)
|
2017-11-01 |
2020-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de composant du complément c3 et leurs procédés d'utilisation
|
WO2019100039A1
(fr)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni de composant p amyloïde serique et leurs procédés d'utilisation
|
CA3084825A1
(fr)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Nouveaux systemes d'endonucleases arn-programmables et leurs utilisations dans l'edition de genome et d'autres applications
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
EP3737689A4
(fr)
|
2018-01-09 |
2021-12-01 |
Cue Biopharma, Inc. |
Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
US11667949B2
(en)
|
2018-02-15 |
2023-06-06 |
The Trustees Of Princeton University |
Reporter construct and biosensor for interferon second messenger 2-5A
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
EP3765092A4
(fr)
|
2018-03-15 |
2022-01-12 |
KSQ Therapeutics, Inc. |
Compositions de régulation génique et procédés pour améliorer l'immunothérapie
|
WO2019183150A1
(fr)
|
2018-03-19 |
2019-09-26 |
Casebia Therapeutics Limited Liability Partnership |
Nouveaux systèmes d'endonucléase à arn programmable et leurs utilisations
|
US20210309756A1
(en)
|
2018-08-09 |
2021-10-07 |
Maverick Therapeutics, Inc. |
Coexpression and purification method of conditionally activated binding proteins
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
CN110857440B
(zh)
|
2018-08-23 |
2021-02-19 |
武汉纽福斯生物科技有限公司 |
重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
|
CN113164556A
(zh)
|
2018-08-30 |
2021-07-23 |
特纳亚治疗股份有限公司 |
用心肌蛋白和ascl1进行的心脏细胞重编程
|
CN111118016B
(zh)
|
2018-10-30 |
2022-04-15 |
上海朗昇生物科技有限公司 |
治疗视网膜色素变性疾病的基因治疗载体
|
US20220025367A1
(en)
|
2018-11-23 |
2022-01-27 |
Sanofi |
Novel rna compositions and methods for inhibiting angptl8
|
TW202039542A
(zh)
|
2018-12-19 |
2020-11-01 |
美商庫爾生物製藥有限公司 |
多聚體t細胞調節多肽及其使用方法
|
KR20210109537A
(ko)
|
2018-12-27 |
2021-09-06 |
에프. 호프만-라 로슈 아게 |
아시네토박터 바우마니의 검출을 위한 비-복제 형질 도입 입자 및 형질 도입 입자 기반의 리포터 시스템
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
EP3934762A1
(fr)
|
2019-03-05 |
2022-01-12 |
Takeda Pharmaceutical Company Limited |
Protéines de liaison à activation conditionnelle limitée
|
EP3934761A1
(fr)
|
2019-03-05 |
2022-01-12 |
Takeda Pharmaceutical Company Limited |
Protéines de liaison activées de manière conditionnelle contenant des régions fc et des fractions ciblant des antigènes tumoraux
|
EP3935080A4
(fr)
|
2019-03-06 |
2023-04-05 |
Cue Biopharma, Inc. |
Polypeptides multimères modulateurs des lymphocytes t et leurs méthodes d'utilisation
|
AU2020231380A1
(en)
|
2019-03-07 |
2021-09-23 |
The Regents Of The University Of California |
CRISPR-Cas effector polypeptides and methods of use thereof
|
US20220145274A1
(en)
|
2019-03-12 |
2022-05-12 |
Crispr Therapeutics Ag |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
CN111718418B
(zh)
|
2019-03-19 |
2021-08-27 |
华东师范大学 |
一种增强基因编辑的融合蛋白及其应用
|
JP2022527860A
(ja)
|
2019-04-02 |
2022-06-06 |
ケンジョッケティ バイオテクノロジー,インク. |
排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
|
JP2022529917A
(ja)
|
2019-04-18 |
2022-06-27 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンの処置及び予後のための方法
|
EP3736330A1
(fr)
|
2019-05-08 |
2020-11-11 |
European Molecular Biology Laboratory |
Particules modifiées du virus adéno-associé (aav) pour la thérapie génique
|
CN112180094A
(zh)
|
2019-07-04 |
2021-01-05 |
上海东慈生物科技有限公司 |
Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
US20220296926A1
(en)
|
2019-07-31 |
2022-09-22 |
Memorial Sloan Kettering Cancer Center |
Perfusion modulated tumor dose sculpting with single dose radiotherapy
|
US20210047425A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
EP4039801A4
(fr)
|
2019-08-16 |
2023-10-18 |
Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences |
Application d'un inhibiteur de ptbp1 dans la prévention et/ou le traitement d'une maladie du système nerveux liée à la mort neuronale fonctionnelle
|
JP2022546040A
(ja)
|
2019-08-27 |
2022-11-02 |
サノフイ |
Pcsk9を阻害するための組成物および方法
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
WO2021087325A1
(fr)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions et méthodes pour rendre silencieuse l'expression du gène de fusion dnajb1-prkaca
|
PE20230179A1
(es)
|
2019-11-13 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
|
WO2021113736A1
(fr)
|
2019-12-05 |
2021-06-10 |
Massachusetts Institute Of Technology |
Anticorps à domaine unique se liant au chloramphénicol
|
US20220356537A1
(en)
|
2019-12-31 |
2022-11-10 |
Roche Molecular Systems, Inc. |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
WO2021154941A1
(fr)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Compositions d'arni du composant c5 du complément destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique (sla)
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
CA3173567A1
(fr)
|
2020-03-02 |
2021-09-10 |
Tenaya Therapeutics, Inc. |
Regulation de vecteur genique au moyen de micro-arn exprimes par des cardiomyocytes
|
GB202004498D0
(en)
|
2020-03-27 |
2020-05-13 |
Ucl Business Ltd |
Activity-dependent gene therapy for neurological disorders
|
MX2022012209A
(es)
|
2020-03-30 |
2022-10-27 |
Wuhan Neurophth Biotechnology Ltd Company |
Vector de expresion del factor 2 relacionado con el factor nuclear humano e2 y aplicacion del vector de expresion.
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CN117377763A
(zh)
|
2020-04-06 |
2024-01-09 |
阿尔尼拉姆医药品有限公司 |
用于沉默myoc表达的组合物和方法
|
CA3179678A1
(fr)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procedes pour le silencage de l'expression de scn9a
|
WO2021237097A1
(fr)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions et procédés d'inhibition de l'expression du gène marc1
|
WO2021247423A1
(fr)
|
2020-06-04 |
2021-12-09 |
Kenjockety Biotechnology, Inc. |
Anticorps multi-spécifiques d'un antigène associé à un cancer-pompe à efflux, ainsi que compositions, réactifs, kits et méthodes associés à ceux-ci
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
WO2022032085A1
(fr)
|
2020-08-07 |
2022-02-10 |
The Jackson Laboratory |
Compositions et procédés d'insertion de séquence ciblée
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
JP2023545502A
(ja)
|
2020-10-16 |
2023-10-30 |
サノフイ |
リポタンパク質(a)を阻害するためのrna組成物および方法
|
WO2022079222A1
(fr)
|
2020-10-16 |
2022-04-21 |
Sanofi |
Nouvelles compositions d'arn et méthodes d'inhibition d'angptl3
|
EP4232581A1
(fr)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Méthodes et compositions pour le traitement de l'hyperoxalurie primaire
|
EP4244209A1
(fr)
|
2020-11-11 |
2023-09-20 |
European Molecular Biology Laboratory |
Particules virales modifiées destinées à la thérapie génique
|
CA3201452A1
(fr)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methodes et compositions pour l'inhibition de l'expression du gene de l'hao1 (hydroxyacide oxydase 1 (glycolate oxydase))
|
WO2022187289A1
(fr)
|
2021-03-01 |
2022-09-09 |
Exuma Biotech Corp. |
Procédés et compositions pour l'administration de particules rétrovirales
|
CA3215344A1
(fr)
|
2021-04-30 |
2022-11-03 |
Kalivir Immunotherapeutics, Inc. |
Virus oncolytiques d'expression de cmh modifiee
|
WO2022234003A1
(fr)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Polypeptides se liant à cd33 avec protéine stefin a
|
IL308896A
(en)
|
2021-06-11 |
2024-01-01 |
Bayer Ag |
Programmable type V RNA endoclase systems
|
EP4101928A1
(fr)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Systèmes d'endonucléase programmables à arn de type v
|
WO2023278576A1
(fr)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Procédés et compositions pour le traitement d'un trouble associé à l'angiotensinogène (agt)
|
EP4144841A1
(fr)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Nouveaux systèmes d'endonucléase programmables à petit arn à spécificité pam améliorée et leurs utilisations
|
WO2023057946A1
(fr)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Polypeptides sériques de liaison pd-l1 prolongés à demi-vie
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
WO2023102388A1
(fr)
|
2021-11-30 |
2023-06-08 |
Sanofi Pasteur Inc. |
Vaccins à base de vecteurs viraux contre le métapneumovirus humain
|
CA3238353A1
(fr)
|
2021-12-13 |
2023-06-22 |
William Robert ARATHOON |
Anticorps anti-abcb1
|
WO2023118068A1
(fr)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Nouveaux petits systèmes programmables d'endonucléases à arn de type v
|
WO2023131682A1
(fr)
|
2022-01-06 |
2023-07-13 |
Ucl Business Ltd |
Régulation des gènes endogènes pour traiter les troubles et maladies neurologiques
|
GB202201744D0
(en)
|
2022-02-10 |
2022-03-30 |
Ucl Business Ltd |
Treatment of acquired focal epilepsy
|
WO2023159220A1
(fr)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anticorps anti-cd47
|
WO2023168305A1
(fr)
|
2022-03-01 |
2023-09-07 |
Exuma Biotech Corp. |
Particules virales comprenant de l'hyaluronidase liée à une membrane
|
WO2023222829A1
(fr)
|
2022-05-17 |
2023-11-23 |
Centre Hospitalier Universitaire Vaudois |
Biocapteurs conçus pour une thérapie de lymphocytes t améliorée
|
WO2023237587A1
(fr)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Nouveaux petits systèmes programmables d'endonucléases à arn de type v
|
WO2024005863A1
(fr)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systèmes et procédés d'édition génomique
|
WO2024005864A1
(fr)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systèmes et procédés d'édition génomique
|
EP4299733A1
(fr)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systèmes et procédés pour l'édition de génomes
|
EP4299739A1
(fr)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systèmes et procédés d'édition de génomes
|
WO2024044659A1
(fr)
|
2022-08-24 |
2024-02-29 |
Tectonic Therapeutic, Inc. |
Compositions de récepteur couplé à une protéine g constitutivement active et leurs procédés d'utilisation
|
WO2024068996A1
(fr)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anticorps anti-sars-cov-2 et utilisation associée dans le traitement d'une infection par sars-cov-2
|
WO2024098061A2
(fr)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Agents thérapeutiques à base d'oligonucléotides ciblant la cycline d2 pour le traitement d'une insuffisance cardiaque
|
WO2024105633A1
(fr)
|
2022-11-18 |
2024-05-23 |
Kyoto Prefectural Public University Corporation |
Compositions pour induction de mitophagie et leurs utilisations
|
WO2024108217A1
(fr)
|
2022-11-18 |
2024-05-23 |
Genkardia Inc. |
Méthodes et compositions pour prévenir, traiter ou inverser un dysfonctionnement diastolique cardiaque
|